Lancet[journal] 检索结果

1261. The CONCORD-Lancet Global Commission on Cancer.

作者: Claudia Allemani.;Gulnar Azevedo E Silva.;Prashant Mathur.;Michel P Coleman.
来源: Lancet. 2024年404卷10450期320-322页

1262. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

作者: Peter Borchmann.;Justin Ferdinandus.;Gundolf Schneider.;Alden Moccia.;Richard Greil.;Mark Hertzberg.;Valdete Schaub.;Andreas Hüttmann.;Felix Keil.;Judith Dierlamm.;Mathias Hänel.;Urban Novak.;Julia Meissner.;Andreas Zimmermann.;Stephan Mathas.;Josée M Zijlstra.;Alexander Fosså.;Andreas Viardot.;Bernd Hertenstein.;Sonja Martin.;Pratyush Giri.;Sebastian Scholl.;Max S Topp.;Wolfram Jung.;Vladan Vucinic.;Hans-Joachim Beck.;Andrea Kerkhoff.;Benjamin Unger.;Andreas Rank.;Roland Schroers.;Christian Meyer Zum Büschenfelde.;Maike de Wit.;Karolin Trautmann-Grill.;Peter Kamper.;Daniel Molin.;Stefanie Kreissl.;Helen Kaul.;Bastian von Tresckow.;Sven Borchmann.;Karolin Behringer.;Michael Fuchs.;Andreas Rosenwald.;Wolfram Klapper.;Hans-Theodor Eich.;Christian Baues.;Athanasios Zomas.;Michael Hallek.;Markus Dietlein.;Carsten Kobe.;Volker Diehl.; .; .; .; .; .
来源: Lancet. 2024年404卷10450期341-352页

Intensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With the new regimen of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD), we aimed to improve the risk-to-benefit ratio of treatment of advanced-stage, classical Hodgkin lymphoma guided by PET after two cycles.

1263. Non-communicable diseases: can implementation research change the game for policy and practice?

作者: Kumanan Rasanathan.;Phyllis Dako-Gyeke.;Wanrudee Isaranuwatchai.;Yodi Mahendradhata.;Morven Roberts.;Giulia Loffreda.;Sarah Rylance.;Bente Mikkelsen.
来源: Lancet. 2024年404卷10466期1908-1910页

1264. Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis.

作者: I Sermet-Gaudelus.;Sihem Benaboud.;Stéphanie Bui.;Tiphaine Bihouée.;Sophie Gautier.; .
来源: Lancet. 2024年404卷10448期117-120页

1265. Mounting evidence in favour of the lower, the better blood pressure paradigm.

作者: Kazem Rahimi.
来源: Lancet. 2024年404卷10449期216-217页

1266. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.

作者: Jiamin Liu.;Yan Li.;Jinzhuo Ge.;Xiaofang Yan.;Haibo Zhang.;Xin Zheng.;Jiapeng Lu.;Xi Li.;Yan Gao.;Lubi Lei.;Jing Liu.;Jing Li.; .
来源: Lancet. 2024年404卷10449期245-255页

Uncertainty exists about whether lowering systolic blood pressure to less than 120 mm Hg is superior to that of less than 140 mm Hg, particularly in patients with diabetes and patients with previous stroke.

1267. Delivering the promise of improved health for women and girls in England.

作者: Jane Elizabeth Hirst.;Alice Witt.;Edward Mullins.;Kate Womersley.;Dorcus Muchiri.;Robyn Norton.
来源: Lancet. 2024年404卷10447期11-14页

1268. Underuse of tranexamic acid in the UK.

作者: Talha Burki.
来源: Lancet. 2024年403卷10446期2772页

1269. Mobile screening for Ukraine's wartime tuberculosis epidemic.

作者: Lily Hyde.
来源: Lancet. 2024年403卷10446期2771页

1270. No parties meeting the challenge on health in the UK.

作者: Udani Samarasekera.
来源: Lancet. 2024年403卷10446期2769-2770页

1271. Multi-system involvement-including purpura fulminans-as an adverse effects of immune checkpoint inhibitor therapy for clear cell renal cell carcinoma.

作者: Chloé Wirbel.;Anne Laure Breton.;Léa Donzier.;Sophie Tartas.;Pierre Curings.;Caroline Pariset.;Emilie Berthoux.
来源: Lancet. 2024年403卷10446期2818-2819页

1272. Targeted release of budesonide in primary IgA nephropathy - Authors' reply.

作者: Richard Lafayette.;Jens Kristensen.;Andrew Stone.;Jonathan Barratt.
来源: Lancet. 2024年403卷10446期2786页

1273. Department of Error.

来源: Lancet. 2024年403卷10446期2786页

1274. Targeted release of budesonide in primary IgA nephropathy.

作者: Yonghua Zou.;Xin Du.;Jianjun Zou.
来源: Lancet. 2024年403卷10446期2785-2786页

1275. Targeted release of budesonide in primary IgA nephropathy.

作者: Yitong Hu.;Yuemiao Zhang.
来源: Lancet. 2024年403卷10446期2785页

1276. Public advocacy crucial in curbing gun violence.

作者: Y Tony Yang.
来源: Lancet. 2024年403卷10446期2784页

1277. Gun violence: a global problem in need of local solutions.

作者: Siddhesh Zadey.;Charles C Branas.;Christopher N Morrison.
来源: Lancet. 2024年403卷10446期2783-2784页

1278. India's forgotten children.

作者: Himmatrao S Bawaskar.
来源: Lancet. 2024年403卷10446期2782页

1279. Reducing scorpion sting fatality rate to 1% in India.

作者: Sujitraj Sheth.;Bin Wang.
来源: Lancet. 2024年403卷10446期2782-2783页

1280. Novel funding pledges for advancing polio eradication efforts.

作者: Ziad A Memish.;Alimuddin Zumla.;Shabir A Madhi.;Abdullah A Al Rabeeah.
来源: Lancet. 2024年403卷10446期2781-2782页

结果排序

文献格式

出版时间

出版类型

出版语言